TL;DR
Checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 are revolutionizing cancer treatment but can cause autoimmune side effects. This study reveals that blocking CTLA-4, but not PD-1, leads to a transient increase in autoreactive B cells, potentially explaining these side effects and also contributing to anti-tumor responses.
What Problem Does This Paper Address?
Cancer immunotherapies that target immune checkpoints, specifically CTLA-4 and PD-1, have shown remarkable success in treating various cancers. However, a significant challenge is the emergence of immune-related adverse events (irAEs), which are essentially autoimmune reactions. While both CTLA-4 and PD-1 are crucial for maintaining immune tolerance, it's been unclear how their blockade specifically impacts the B cell repertoire, particularly concerning autoreactive B cells that could drive these irAEs. This paper aims to dissect the distinct roles of CTLA-4 and PD-1 in regulating B cell tolerance, focusing on how their inhibition affects the development and selection of autoreactive B cells.
Methods
The researchers employed a multi-pronged approach:
- B Cell Repertoire Analysis: They isolated B cells from cancer patients before and after treatment with checkpoint inhibitors (CPIs). Recombinant antibodies were generated from single B cells and tested for reactivity against self-antigens (like dsDNA, insulin, LPS, and HEp-2 cells) using ELISA. This allowed them to quantify the frequency of autoreactive B cells.
- Humanized Mouse Models: To further investigate the mechanisms, they used humanized mice (NOD-scid IL2Rγnull mice engrafted with human hematopoietic stem cells and thymic tissue). These mice were treated with anti-CTLA-4, anti-PD-1, or isotype control antibodies. B cells from these mice were then analyzed for autoreactivity.
- Single-Cell RNA Sequencing (scRNA-seq): scRNA-seq was used to analyze the transcriptomic profiles of B cells and CD4+ T cells (specifically regulatory T cells, or Tregs) from patients at different time points during treatment. This helped identify changes in cell populations and gene expression patterns.
- Rapid Extracellular Antigen Profiling (REAP): This high-throughput yeast-based technology was used to characterize the specific antigens recognized by autoreactive B cell-derived antibodies.
Datasets
The study utilized:
- Patient Samples: Peripheral blood mononuclear cells (PBMCs) from cancer patients undergoing treatment with anti-CTLA-4 and/or anti-PD-1 checkpoint inhibitors.
- Humanized Mouse Models: Spleen and blood samples from humanized mice treated with CPIs.
- Fetal Tissues: Human fetal tissues (bone marrow, spleen, liver, thymus) were used to generate the humanized mouse models.
No new benchmarks were introduced; the study focused on analyzing existing biological systems and patient data.
Key Insights and Ideas
- CTLA-4, Not PD-1, is the Gatekeeper for Autoreactive B Cells: The most striking finding is that CTLA-4 blockade, but not PD-1 blockade, leads to a significant increase in autoreactive mature naive B cells. This suggests CTLA-4 plays a critical, previously underappreciated role in eliminating these potentially harmful B cells.
- Central Tolerance Remains Intact: The study confirmed that neither CTLA-4 nor PD-1 blockade disrupts central B cell tolerance in the bone marrow, as evidenced by the normal frequencies of autoreactive B cells in transitional B cell populations.
- Peripheral Tolerance is the Target: The impact of CTLA-4 blockade is specifically on the peripheral tolerance checkpoint, which normally filters out autoreactive B cells that escape central tolerance.
- Autoreactive B Cells Recognize Tissue-Specific Antigens: REAP analysis revealed that some of the autoreactive B cells generated after CTLA-4 blockade recognize antigens found in tissues commonly affected by irAEs (e.g., skin, heart, thyroid, brain).
- Tregs are Affected by Combination Therapy: scRNA-seq showed an expansion and altered transcriptional profile of regulatory T cells (Tregs) in patients treated with combination therapy, suggesting a complex interplay between T cells and B cells during treatment.
- Broader Repertoire Implications: The findings suggest that CTLA-4 blockade broadens the peripheral B cell repertoire, which could be beneficial for anti-tumor responses by including B cells that recognize tumor antigens, but also detrimental by allowing autoreactive clones to emerge.
Key Results
- Anti-CTLA-4 and anti-PD-1 combination therapy significantly increased the frequency of HEp-2-reactive (54% vs. 17%) and polyreactive (37.3% vs. 8.5%) mature naive B cells in cancer patients.
- These increases were transient, returning to baseline levels when anti-CTLA-4 treatment was stopped.
- Anti-PD-1 monotherapy did not alter autoreactive B cell frequencies in either patients or humanized mice.
- Anti-CTLA-4 injections in humanized mice, but not anti-PD-1, led to a significant accumulation of autoreactive mature naive B cells.
- Specific autoreactive clones identified after CTLA-4 blockade recognized antigens like dermatopontin (DPT) and lipocalin 1-like protein 1 (LCN1P1), which are expressed in irAE-targeted organs.
- scRNA-seq identified an expansion of a specific Treg cluster (cluster 2) in patients treated with combination therapy, characterized by the upregulation of genes like CXCR3 and FOXP3.
Limitations and Future Work
- Transient Nature of Autoreactivity: The study highlights that the emergence of autoreactive B cells is transient, which is a key observation but also means long-term consequences require further investigation.
- Limited Patient Numbers for Specific Analyses: While the study used multiple patients, some analyses, particularly scRNA-seq, were performed on a limited number of individuals.
- Potential for Anti-Tumor Role: The paper acknowledges that the broadened repertoire might also include B cells that recognize tumor antigens, suggesting a potential benefit for anti-tumor immunity. This duality warrants further exploration.
- Timing of Anti-B Cell Therapy: The authors suggest that anti-B cell therapy could potentially prevent irAEs, but this might compromise anti-tumor responses. Determining the optimal timing for such interventions is a critical area for future research.
- Investigating Tumor-Infiltrating B Cells: Future studies are needed to examine the reactivity of B cells within tumors and identify the specific antigens they recognize, which could provide deeper insights into their role in anti-tumor immunity.
Summary updated